Meibum Scientific announced the appointment of Ryan S. Bleeks as interim CEO. The appointment comes as the company accelerates commercialization of its flagship technologies, BlephEx and OptiVize.

Most recently, Bleeks served as CEO of Visiox Pharmaceuticals, where he oversaw the company’s definitive merger agreement with Ocuvex Therapeutics. He also led Visiox’s acquisition of the US license for Omlonti from Santen Pharmaceuticals.